Tiglutik (Riluzole Oral Suspension) for ALS

Last updated January 16, 2023, by Teresa Carvalho, MS

✅ Fact-checked by Inês Martins, PhD

What is Tiglutik for ALS?

Tiglutik (riluzole oral suspension) is a liquid formulation of riluzole approved for treating amyotrophic lateral sclerosis (ALS). It can be taken orally or administered through a feeding tube inserted directly into the stomach, called a PEG tube.

It’s marketed by ITF Pharma in the U.S and Martindale Pharma in Europe, where it’s sold under the name Teglutik. Other formulations of riluzole are also available for ALS, including a tablet formulation called Rilutek (with generics also available) and an oral film formulation called Exservan.

How does Tiglutik work?

Glutamate is a neurotransmitter, or chemical messenger, needed for nerve cells to communicate with each other. Excessive levels of this neurotransmitter, however, can cause damage to nerve cells by making them fire too much. This is thought to be one of the mechanisms driving ALS.

The exact mechanism of action of riluzole-based medications in ALS is not well understood. But studies suggest the compound improves nerve cell health by inhibiting glumatate signaling and lowering the amount of TDP-43 protein clumps in cells, which is also thought to contribute to nerve cell death in ALS.

Who can use Tiglutik?

The U.S. Food and Drug Administration (FDA) first approved Tiglutik in 2018 as an oral treatment with ALS. That was later expanded to include feeding tube administration, making Tiglutik the first and only riluzole formulation approved for both oral and PEG tube use.

The medication is also approved under the brand name Teglutik in multiple European Countries, as well as in Israel and Turkey.

Who should not use Tiglutik?

The medication should not be used in people with severe allergies to either riluzole or any other component in Tiglutik. It’s also not recommended for people with elevated levels of liver enzymes.

How is Tiglutik administered?

Tiglutik is available in an amber glass bottle containing 300 mL of a brown, opaque oral suspension. Each 1 mL of riluzole oral suspension contains 5 mg of active drug.

The recommended dosage is 50 mg, given via an oral syringe containing 10 mL of the suspension, taken twice daily (every 12 hours). It should be administered at least one hour before or two hours after a meal.

The suspension can be taken by mouth wherein an oral syringe containing 10 mL of the medication is placed toward the inside of the cheek and slowly emptied, or given through a PEG tube. In this case, the PEG tube should be flushed with one ounce (nearly 30 mL) of water before and after each administration.

Tiglutik should be stored at room temperature, upright and protected from light. Each bottle should be used within 15 days of opening and kept tightly closed between each use.

Tiglutik in clinical trials

Tigkutik’s approvals were supported by results from two clinical trials of Rilutek, wherein the tablet formulation significantly extended the time to death or needing a breathing tube (tracheostomy) compared with a placebo.

The approval package also included data from bioavailability studies in healthy volunteers showing Tiglutik is comparable to Ritlutek in terms of total exposure to riluzole. However, riluzole was more rapidly absorbed into circulation and reached a peak concentration about 20% higher with Tiglutik.

Common side effects of Tiglutik

The most common side effects of Tiglutik include:

  • numbness in the mouth
  • generalized weakness
  • nausea
  • reduced lung function
  • high blood pressure
  • abdominal pain

Liver damage

Based on Rilutek clinical trials, riluzole-based medications like Tiglutik may cause liver damage. Patients should be monitored regularly for this potentially life-threatening side effect and discontinue treatment if they develop signs of liver impairment. Tiglutik is also not recommended for patients with elevated levels of liver enzymes.

Low levels of white blood cells

Neutropenia, a condition characterized by lower than normal levels of immune neutrophils, has been reported within the first months of Tiglutik treatment. Because the condition is often accompanied by a fever, patients should report any increases in temperature to their healthcare provider.

Lung scarring

The medication may lead to interstitial lung disease, or “scarring” of lung tissue and should be immediately discontinued if this form of lung disease develops.

Use in pregnancy and breastfeeding

Tiglutik has not been adequately studied in pregnant people, but animal data suggests it may cause harm to a developing fetus. It’s also not known if it can pass to breast milk.

It’s recommended that patients who are or plan to become pregnant or to breastfeed talk with their healthcare team about the potential risks and benefits of Tiglutik treatment during these periods.

ALS News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.